CONTENTS:
- Why we should conduct research in collaboration with people who use alcohol and other drugs [Editorial]. Neale J., Bouteloup A., Getty M., Hogan C., Lennon P., Mc Cusker M., et al., p. 2084-2085.
- Precision medicine and pharmacogenetics: what does oncology have that addiction medicine does not? [Addiction debate]. Kranzler H.R., Smith R.V., Schnoll R., Moustafa A., Greenstreet-Akman E., p. 2086-2094.
- Challenges the addiction field must overcome to avert being the Cinderella of medicine. Lingford-Hughes A., p. 2095-2096.
- Precision medicine in addiction research: where has the time gone? Oliver J.A., McClernon F.J., p. 2096-2097.
- The experience of initiating injection drug use and its social context: a qualitative systematic review and thematic synthesis. Guise A., Horyniak D., Melo J., McNeil R., Werb D., p. 2098-2111.
- Who achieves low risk drinking during alcohol treatment? An analysis of patients in three alcohol clinical trials. Witkiewitz K., Pearson M.R., Hallgren K.A., Maisto S.A., Roos C.R., Kirouac M., et al., p. 2112-2121.
- Commentary on Witkiewitz et al. (2017): Abstinence or moderation - a choice for whom and why? Storbjörk J., p. 2122-2123.
- Heavy alcohol consumption increases the risk of active tuberculosis in Taiwanese adults: a nation-wide population-based cohort study. Yen Y.-F., Hu H.-Y., Lee Y.-L., Ku P.-W., Chuang P.-H., Lai Y.-J., et al., p. 2124-2131.
- Self-reported cognitive scales in a US National Survey: reliability, validity, and preliminary evidence for associations with alcohol and drug use. Aharonovich E., Shmulewitz D., Wall M.M., Grant B.F., Hasin D.S., p. 2132-2143.
- Structural neuroimaging correlates of alcohol and cannabis use in adolescents and adults. Thayer R.E., YorkWilliams S., Karoly H.C., Sabbineni A., Ewing S.F., Bryan A.D., et al., p. 2144-2154.
- A pilot randomized clinical trial testing integrated 12-Step facilitation (iTSF) treatment for adolescent substance use disorder. Kelly J.F., Kaminer Y., Kahler C.W., Hoeppner B., Yeterian J., Cristello J.V., et al., p. 2155-2166.
- Variation in cannabis potency and prices in a newly legal market: evidence from 30 million cannabis sales in Washington state. Smart R., Caulkins J.P., Kilmer B., Davenport S., Midgette G., p. 2167-2177.
- Potency increase, product development and marijuana marketing in times of legalization. Carlini B.H., p. 2178-2179.
- The need for better marijuana sales data. Williams J., Banta-Green C., Burgard D., p. 2179-2180.
- Response to Commentaries: new data sources for understanding cannabis markets. Smart R., Caulkins J.P., Kilmer B., Davenport S., Midgette G., p. 2180-2181.
- Associations between anhedonia and marijuana use escalation across mid-adolescence. Leventhal A.M., Cho J., Stone M.D., Barrington-Trimis J.L., Chou C.-P., Sussman S.Y., et al., p. 2182-2190.
- Rates, characteristics and circumstances of methamphetamine-related death in Australia: a national 7-year study. Darke S., Kaye S., Duflou J., p. 2191-2201.
- What is the real distribution of methamphetamine-related causes of death? Kuo C.-J., Chen C.-C., p. 2202-2203.
- Why methamphetamine-related deaths need more attention. McKetin R., p. 2203-2204.
- Methamphetamine-related death is an under-addressed public health problem. Darke S., Kaye S., Duflou J., p. 2204-2205.
- Mapping medical marijuana: state laws regulating patients, product safety, supply chains and dispensaries, 2017. Klieger S.B., Gutman A., Allen L., Pacula R.L., Ibrahim J.K., Burris S., p. 2206-2216.
- A free ride? An analysis of the association of casino bus tours and problem gambling among older adults. van der Maas M., Mann R.E., Matheson F.I., Turner N.E., Hamilton H.A., McCready J., p. 2217-2224.
- Commentary on van der Maas et al. (2017): Going where the action is. Markham F., Young M., p. 2225-2226.
- Accuracy of self-reported smoking abstinence in clinical trials of hospital-initiated smoking interventions. Scheuermann T.S., Richter K.P., Rigotti N.A., Cummins S.E., Harrington K.F., Sherman S.E., et al., p. 2227-2236.
- Effectiveness of intensive practice nurse counselling versus brief general practitioner advice, both combined with varenicline, for smoking cessation: a randomized pragmatic trial in primary care. van Rossem C., Spigt M., Viechtbauer W., Lucas A.E.M., van Schayck O.C.P., Kotz D., p. 2237-2247.
- The association between personal income and smoking among adolescents: a study in six European cities. Perelman J., Alves J., Pfoertner T.-K., Moor I., Federico B., Kuipers M.A.G., et al., p. 2248-2256.
- Setting research priorities in tobacco control: a stakeholder engagement project. Lindson N., Richards-Doran D., Heath L., Hartmann-Boyce J., CTAG taps team, p. 2257-2271.
- Risk, individual perception of risk and population health. Shield K.D., Gmel G., Mäkelä P., Probst C., Room R., Gmel G., et al., p. 2272-2273.